Venous thromboembolism (VTE) is a significant clinical and economic burden. Up to 600,000 new or recurrent cases of nonfatal, symptomatic VTE occur each year in the US, with an additional 300,000 VTE-related deaths. 1,2 Estimated annual VTE-related costs to the US health care system range from $500 million to more than $1.5 billion. 3Conventionally, patients diagnosed with deep vein thrombosis (DVT) or pulmonary embolism (PE) receive continuous infusion intravenous unfractionated heparin as an inpatient until warfarin is appropriately titrated to a therapeutic international normalized ratio (INR). There is reliable evidence that outpatient treatment of VTE with low-molecular-weight heparins or fondaparinux is cost

No abstract

No abstract